Thor Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 7

Thor Therapeutics General Information

Description

Developer of biopharmaceutical therapeutics designed to treat cancer cachexia and metabolic dysfunction. The company combines modern genetic, molecular biology, and structural biology techniques coupled with computational expertise to efficiently validate novel biological and chemical therapeutics across various targets, including membrane receptors, hormones, and ligand-receptor interactions, enabling the health industry to develop preclinical monoclonal antibody and antisense oligonucleotide candidates for novel therapeutic targets.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • A203, Startup Square, 40, Geumto-ro 80beon-gil
  • Sujeong-gu 13453
  • Seongnam, Gyeonggi-do
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Corporate Office
  • A203, Startup Square, 40, Geumto-ro 80beon-gil
  • Sujeong-gu 13453
  • Seongnam, Gyeonggi-do
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Thor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 30-Oct-2026 Completed Pre-Clinical Trials
2. Accelerator/Incubator 23-Mar-2023 Completed Pre-Clinical Trials
1. Seed Round Completed Startup
To view Thor Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Thor Therapeutics Patents

Thor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025274035-A1 Monoclonal antibody targeting gfral and use thereof Pending 24-May-2024
WO-2025244462-A1 Monoclonal antibody targeting gfral and use thereof Pending 24-May-2024
EP-4653531-A1 Antisense oligomers targeting gfral and use thereof Pending 20-Jan-2023
US-20260218200-A1 Antisense oligomers targeting gfral and use thereof Pending 20-Jan-2023
WO-2024155160-A1 Antisense oligomers targeting gfral and use thereof Inactive 20-Jan-2023 A61P35/00
To view Thor Therapeutics’s complete patent history, request access »

Thor Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Thor Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alteogen Corporation Minority
BetterLuck Partners Corporation Minority
BioHealthcare Association Corporation Minority
The Iroun Partners Venture Capital Minority
Tech Incubator Program for Startup Accelerator/Incubator
You’re viewing 5 of 7 investors. Get the full list »

Thor Therapeutics FAQs

  • When was Thor Therapeutics founded?

    Thor Therapeutics was founded in 2022.

  • Where is Thor Therapeutics headquartered?

    Thor Therapeutics is headquartered in Seongnam, South Korea.

  • What is the size of Thor Therapeutics?

    Thor Therapeutics has 3 total employees.

  • What industry is Thor Therapeutics in?

    Thor Therapeutics’s primary industry is Drug Discovery.

  • Is Thor Therapeutics a private or public company?

    Thor Therapeutics is a Private company.

  • What is Thor Therapeutics’s current revenue?

    The current revenue for Thor Therapeutics is .

  • Who are Thor Therapeutics’s investors?

    Alteogen, BetterLuck Partners, BioHealthcare Association, The Iroun Partners, and Tech Incubator Program for Startup are 5 of 7 investors who have invested in Thor Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process